ESMO 2022
Endocrine response in eBC
ADAPT & ADAPTcycle
ESMO 2022
Endocrine response in eBC
DATA
ESMO 2022
Roadmap for the adjuvant setting
GIM
ESMO 2022
Long-term data on dose density therapy in chemotherapy
GIM
ESMO 2022
Dose-dense standard of care is the optimal care
GIM
ESMO 2022
Dose-dense therapy is beneficial for all patients
BELLINI
ESMO 2022
Immuntherapy only for low risk patients?
Polar
ESMO 2022
Hand cooling and compression both effective in…
TROPiCS-02, Monarch3, GIM, DATA
ESMO 2022
My highlights of ESMO22
GIM
ESMO 2022
DD is the champion!
POLAR
ESMO 2022
Reduction of peripheral neuropathy with taxane therapy
KEYNOTE-522
ESMO 2022
QoL and longterm toxicity
ESMO 2022
Simple and cheap surgical technique may impact survival…
GIM
ESMO 2022
Dose dense is better
GIM, MONARCH-3, TEAMS, monarchHER, KEYNOTE-522, ADAPT
ESMO 2022
Consolidating data from prospective studies
GIM
ESMO 2022
Il vincitore e’ il dose dense!!
Polar
ESMO 2022
Chłodzenie rąk i terapia kompresyjna skutecznie…
TROPiCS-02, Monarch3, GIM, DATA
ESMO 2022
I miei punti salienti di ESMO22
GIM
ESMO 2022
Schéma dose-dense bénéfique pour toutes les patientes
ESMO 2022
Rosta i tania technika chirurgiczna może wpływać na…
GIM, MONARCH-3, TEAMS, monarchHER, KEYNOTE-522, ADAPT
ESMO 2022
Datele trialurilor se consolideata
DATA
ESMO 2022
DATA: Still open questions on the optimal duration of…
GIM
ESMO 2022
Dose-dense CT Efficacy confirmed in the Nodal+ ER+…
KEYNOTE-522, Bellini
ESMO 2022
Status update - adjuvant IO. Are TILs prognostic?
AMEERA, aceLERA
ESMO 2022
How to deal with the negative SERD data?
ADAPT&ADAPTcylce
ESMO 2022
Who needs Chemo? Who does not? Is OFS plus endocrine…
ADAPT&ADAPTcycle, DATA, GIM
ESMO 2022
Tailoring Adjuvant Therapy
ESMO 2022
Unmeet needs and my wishes for 2022!
TROPiCS-02
ESMO 2022
ADC after ADC - is there any orientation?
MONARCH-3
ESMO 2022
Interim analysis shows promising data on Abema in the…
MonarcHER
ESMO 2022
Endocrine-based therapy may prove more effective than…
monarcHER
ESMO 2022
HER2+ and still without chemotherapy
TROPiCS-02
ESMO 2022
Another option for heavily pre-treated HR+ advanced…
TROPiCS-02
ESMO 2022
SG is a novel treatment option for HR+/HER2- disease
AMEERA-3, acelERA BC
ESMO 2022
Negative and yet positive?!
TROPiCS-02
ESMO 2022
New data re-inforces SG as a new option pre-treated…
DAISY
ESMO 2022
Update on biomarkers on ADCs of the DAISY trial
monarcHER
ESMO 2022
CDK4/6i could be an option for selected ER+/HER2+…
METEORA-II trial
ESMO 2022
VEX has no place in chemotherapy of metastatic breast…
TROPiCS-02, Monarch3, GIM, DATA
ESMO 2022
My highlights of ESMO22
TROPiCS-02
ESMO 2022
Sacituzumab govitecan for everybody!
TROPiCS-02
ESMO 2022
New treatment option for heavily pre-treated patients…
TROPiCS-02
ESMO 2022
TROPiCS-02 highlights
ELAINE
ESMO 2022
Exciting data, but Phase 3 studies are needed
MONARCH-3
ESMO 2022
The third in the bunch
MONARCH-3
ESMO 2022
OS not significant, but re-assuring new data
monarcHER
ESMO 2022
More therapy options for patients with HR+, HER2+…
TROPiCS-02
ESMO 2022
Survival benefit from SG in mBC
MONARCH3
ESMO 2022
Survival benefit in endocrine sensitive patients
Ameera
ESMO 2022
Discontinued development
TROPiCS-02, Monarch3, GIM, DATA
ESMO 2022
I miei punti salienti di ESMO22
TROPiCS-02
ESMO 2022
TROPiCS-02 highlights
monarcHER
ESMO 2022
Nuove opzioni di trattamento personalizzate per…
TROPiCS-02
ESMO 2022
Sacituzumab Govitecan: Un farmaco per tutte?
DAISY
ESMO 2022
Nouvelles données des analyses expolratoires dans…
MONARCH-3
ESMO 2022
Survie globale pas encore significative statistiquement…
MONARCH3
ESMO 2022
Sopravvivenza globale nello studio MONARCH3
MonarcHER
ESMO 2022
Leczenie zaawansowanych raków „potrójnie dodatnich”…
TROPiCS-02
ESMO 2022
Nouvelle option thérapeutique pour les patientes…
TROPiCS-02
ESMO 2022
SG come nuova opzione di cura Per pazienti con tumore…
MONARCH 3, DAWNA-2, monarcHER
ESMO 2022
Monarch-3: strong OS Survival; DAWNA-2: PFS in line…
monacHER
ESMO 2022
CDK4/6i plus Trastuzumab – a possible chemo-free option…
MONARCH-3
ESMO 2022
Interim OS Data & PFS Update for Abemaciclib hint…
acelERA BC, AMEERA-3
ESMO 2022
SERDs: equal PFS benefit vs. endocrine therapy;…
TROPiCS-02
ESMO 2022
SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd…
TROPiCS
ESMO 2022
ADC efficacy in perspective: SG overall survival…
ADAURA
ESMO 2022
ADAURA Update - preventing relapse or just delaying it?
ESMO 2022
Liquid biopsy monitoring of EGFR-mutant lung cancer…
ADAURA
ESMO 2022
Osimertinib - curing or delaying relapse?
ADAURA
ESMO 2022
Osimertinib stays standard adjuvant
ADAURA
ESMO 2022
Is OS really needed?
ADAURA
ESMO 2022
ADAURA revisited
ESMO 2022
Pollution and lung cancer - one mechanism revealed
INCREASE
ESMO 2022
Double IO + chemoradiotherapy - is it feasible in…
NeoCOAST
ESMO 2022
Window for treatment selection
INCREASE
ESMO 2022
INCREASE - to good to be true?
ADAURA
ESMO 2022
Long term follow-up of ADAURA trial
INCREASE
ESMO 2022
Concurrent preoperative IO/CRT in early lung cancer
INCREASE
ESMO 2022
Neoadjuvant strategies for PD-L1 < 1 %
ADAURA
ESMO 2022
Osimertinib: una cura o ritarda la ripresa di malattia?
ESMO 2022
Pollution et cancer du poumon - un mécanisme mis en…
ADAURA
ESMO 2022
ADAURA revisited
INCREASE
ESMO 2022
Dubbele immunotherapie plus chemoradiotherapie - is het…
NeoCOAST
ESMO 2022
Eine Plattform für "take the winner"-Strategie
ADAURA
ESMO 2022
Osimertinib bleibt Standard adjuvant
ESMO 2022
Liquid biopsie monitoring van patiënten met een EGFR…
ADAURA
ESMO 2022
Langzeitdaten ADAURA
INCREASE, CheckMate 816
ESMO 2022
Important data on borderline resectable patients
ADAURA
ESMO 2022
DFS matters!
DICIPLE
ESMO 2022
Can IO be discontinued?
CodeBreak 200
ESMO 2022
Sotorasib vs. Docetaxel in mKRAS G12C
KEYNOTE-189, KEYNOTE-407
ESMO 2022
Long term follow-up of KEYNOTE-189 and KEYNOTE-407
CodeBreaK 200
ESMO 2022
Sotorasib - a new standard of care?
KEYNOTE-189, KEYNOTE-407
ESMO 2022
5-year update on 1st line chemoimmunotherapy
IPSOS
ESMO 2022
Atezolizumab better than vinorelbin in reduced…
DESTINY-Lung02
ESMO 2022
HER2 - the next actionable mutation in lung cancer?
CodeBreaK 200
ESMO 2022
A new step in treatment of KRAS G12C mutant NSCLC
IPSOS
ESMO 2022
New immunotherapy options for pts. ineligible to 1st…
DESTINY-Lung02
ESMO 2022
Pneumonitis and T-DXd
EMPOWER-Lung 1
ESMO 2022
Cemiplimab beyond progression?
CodeBreaK 200
ESMO 2022
Sotorasib: sweet and sour results
CodeBreaK 200
ESMO 2022
The journey at KRAS G12C continues
ELIOS, INSIGHT 2
ESMO 2022
If you don't look, vou don't find - once you found it,…
KEYNOTE-189, KEYNOTE-407
ESMO 2022
5 years of chemoimmunotherapy: solid grounded
KEYNOTE-189, KEYNOTE-407
ESMO 2022
5-year data on survival under immunotherapy
DICIPLE
ESMO 2022
Duration of immunotherapy : Stop and go strategy for…
IPSOS
ESMO 2022
Immunotherapy in unfit population? Perhaps...
INSIGHT 2
ESMO 2022
New therapy combination after progression on 1L…
KEYNOTE-189, KEYNOTE-407, POSEIDON
ESMO 2022
Chemoimmunotherapy - improvement of survival after 5…
CodeBreaK 200
ESMO 2022
One more brick in the KRAS G12C wall
IPSOS
ESMO 2022
Emerging IO mono options in the first line
IPSOS
ESMO 2022
Can we finally treat poor prognostic patients with…
DICIPLE
ESMO 2022
Is shorter immunotherapy equally effective and less…
POSEIDON
ESMO 2022
Poseidon and STK11/KEAP
ESMO 2022
Preview on lung cancer highlights
DESTINY-Lung02
ESMO 2022
DESTINY-Lung02 - better than the original?
IMreal
ESMO 2022
Real-world data on Atezolizumab
APPLE
ESMO 2022
Liquid biopsy monitoring in treatment decisions
DICIPLE
ESMO 2022
Question about timing and duration of immunotherapy…
INCREASE
ESMO 2022
Induction chemoimmunotherapy in borderline…
CodeBreaK 200
ESMO 2022
Un mattone in piu' nel muro del KRAS G12C
IPSOS
ESMO 2022
Atezo besser als Vino bei PS2-3
IMreal
ESMO 2022
Données de vie réelle avec l’atezolizumab
CodeBreaK 200
ESMO 2022
Une nouvelle étape dans le traitement du CBNPC KRAS…
DICIPLE
ESMO 2022
Kürzere Immuntherapie gleich effektiv aber weniger…
CodeBreak 200
ESMO 2022
Sotorasib vs. Docetaxel bei mKRAS G12C
DICIPLE
ESMO 2022
Kann IO pausiert werden?
EMPOWER-Lung 1
Cemiplimab beyond progression?
INCREASE
ESMO 2022
IO-IO neoadjuvant bei PD-L1 neg.
Keynote-189, KEYNOTE-407
ESMO 2022
5 Jahre Chemo-Immuntherapie: starker Effekt
KEYNOTE-189, KEYNOTE-407, POSEIDON
ESMO 2022
Chimio-immunothérapie - amélioration de la survie après…
IPSOS
ESMO 2022
Kunnen we eindelijk patiënten met een slechte prognose…
INSIGHT 2
ESMO 2022
Neue Therapiekombination in der Resistenz nach…
INCREASE
ESMO 2022
Chemo-IO-Induktion bei grenzwertiger Resektabilität?
ESMO 2022
Les études incontournables à l’ESMO 2022
IPSOS
ESMO 2022
Una nueva opción de tratamiento con IO en pacientes no…
DICIPLE
ESMO 2022
Durée de l'immunothérapie : stratégie Stop and Go pour…
CodeBreaK 200
ESMO 2022
Resultados Agridulces de Sotorasib
APPLE
ESMO 2022
Liquid Biopsy Monitoring zur Therapiesteuerung
CodeBreaK 200
ESMO 2022
Die Reise bei KRAS G12C geht weiter
DESTINY-Lung02
ESMO 2022
Pneumonitis und T-DXd
POSEIDON
ESMO 2022
Poseidon und STK11/KEAP
IPSOS
ESMO 2022
Neue Option der IO-Therapie in der Erstlinie
Sacha Rothschild, MD
ESMO 2022
5-Jahresüberleben mit Immuntherapie
ELIOS, INSIGHT 2
ESMO 2022
Se non lo cerchi non lo troiv. Quando lo hai trovato,…
IPSOS
ESMO 2022
Immunoterapia nella popolazione non fit: forse
APPLE, ELIOS, INSIGHT 2
ESMO 2022
Heterogenity in the genetic landscape - little progress…
CodeBreaK 200
ESMO 2022
A positive study! With a question mark?
EMPOWER-Lung 1, KEYNOTE-189, KEYNOTE-407
ESMO 2022
Novel data and long-term efficacy of chemo-IO in mNSCLC
DICIPLE, IPSOS
ESMO 2022
New strategies in immunotherapy
CheckMate914
ESMO 2022
No value of IPI/Nivo in the adjuvant setting.
IMmotion010, CheckMate 914
ESMO 2022
News in terms of adjuvant
COSMIC-313
ESMO 2022
Exciting data for high-risk patients: is this the start…
CheckMate914, IMmotion101, PROSPER
ESMO 2022
Adjuvant Immuntherapy in kidney cancer
COSMIC-313
ESMO 2022
New combo - triplet therapy for kidney cancer
CheckMate914, IMmotion101, PROSPER, COSMIC-313, and more
ESMO 2022
Brief highlights about RCC & urothelial cancer from…
PROSPER
ESMO 2022
More questions being raised
CheckMate914; IMmotion101
ESMO22
Two negative studies question adjuvant approach in RCC
COSMIC-313
ESMO 2022
Place of triplet therapy
IMmotion101, Checkmate 914, PROSPER
ESMO 2022
Immune-based peri-operative treatment in RCC: What went…
IMmotion010, CheckMate 914
ESMO 2022
Adjuvant CPI in kidney cancer – 2 phase III trials with…
CheckMate914, IMmotion101, PROSPER
ESMO 2022
Inmunoterapia adyuvante en el cancer renales
CheckMate914, IMmotion101, PROSPER, COSMIC-313
ESMO 2022
Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού
COSMIC-313
ESMO 2022
Terapia triple para cancer renales
IMmotion101, Checkmate 914, PROSPER
ESMO 2022
Tratamiento perioperatorio con immunoterapia en cáncer…
PIVOT-09
ESMO 2022
Immunomodulation in combination with…
CLEAR, KEYNOTE-B61
ESMO 2022
Shedding light on TKI/Checkpointinhibitor combinations
COSMIC-313, TITAN-RCC
ESMO 2022
Therapy combinations in RCC - what is the role of…
CheckMate914, IMmotion101, PROSPER
ESO 2022
Adjuvant immunotherapy options in RCC - what do we…
LBA73
ESMO 2022
EV + pembrolizumab in cisplatin-ineligible patients
CheckMate914, IMmotion101, PROSPER, COSMIC-313, and more
ESMO 2022
Brief highlights about RCC & urothelial cancer from…
EV-103 Cohort K
ESMO 2022
EV + Pembro with excellent response rates
EV-103, JAVELIN-Bladder100, IMvigor130
ESMO 2022
Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο
JAVELIN-Bladder100, IMvigor130
ESMO 2022
Biomarker exploration in urothelial cancer - finding…
RACE IT
ESMO 2022
Adjuvant and neoadjuvant therapy approaches in…
EV-103
ESMO 2022
Promising data, but beware of toxicity
ESMO 2022
ADCs - a possible therapeutic approach
CABASTY
ESMO 2022
Optimizing cabazitaxel chemotherapy
VISION
ESMO 2022
Further evaluation of PSA correlates
ARCHES
ESMO 2022
ADT + ENZA better choice than monotherapy
PEACE-1
ESMO 2022
PSA at 8-months as a biomarker
PRESTO
ESMO 2022
Should intensification of ADT be considered in…
RADICALS-HD
ESMO 2022
Length of hormone therapy after radiation
PROpel
ESMO 2022
Update on the PROpel study
ARASENS
ESMO 2022
QoL data from ARASENS triplet therapy study mHRPC
PROpel
ESMO 2022
Genetic testing before PARP therapy is useful
ENACT
ESMO 2022
Biomarker data for better patients selection
PROpel
ESMO 2022
Combination of olaparib leads to promising results
CABASTY
ESMO 2022
In older vulnerable - less is more
ARASENS
ESMO 2022
Triplet therapy with darolutamide in prostate cancer
P1/2a study of PRL-02
ESMO 2022
IM arbiraterone decanoate might demonstrate superior…
ESMO 2022
Cabazitaxel better tolerated in elderly men
KEYLYNK-010
ESMO 2022
IO + PARP without benefit in the allcomer situation
RADICALS HD
ESMO 2022
Radicals - ADT & Radiotherapy
ARASENS
ESMO 2022
Livskvalitetsuppföljning i ARASENS studien
PEACE-1
ESMO 2022
PSA efter 8 månader i PEACE-1 studien som biomarkör
PROpel
ESMO 2022
Uppdatering i PROpel studien
ESMO 2022
Intimate partner violence in cancer patients
ESMO 2022
TILs - Fashion is the eternal return of the old
BNT211-01
ESMO 2022
Novel approach von Biontech towards Cancer – game…
KEYNOTE-412
ESMO 2022
Addition of CPI to Radiochemotherapy in LA-HNSCC?
ESMO2 022
IAP-inhibition – comming game changer in LA-HNSCC…
DeFi
ESMO 2022
New group of substances for rare diseases
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!